

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 2637)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD
ON 27 MAY 2026, CHANGE OF DIRECTORS, ELECTION OF
CHAIRMAN AND APPOINTMENT OF SENIOR MANAGEMENT,
CHANGE IN COMPOSITION OF BOARD COMMITTEE AND
ABOLISHMENT OF THE BOARD OF SUPERVISORS**

At the annual general meeting (the “AGM”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “Company”) held at Conference Room, Floor 1, Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou, Fujian Province, the PRC on 27 May 2026 at 10:00 a.m., all the resolutions as set out in the notice of the AGM of the Company dated 30 April 2026 were taken by poll on a one share one vote basis.

The AGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Articles of Association. The AGM was chaired by the Mr. Kang Xinshan, the Chairman of the Board.

The poll results of the AGM are as follows:

Ordinary Resolutions		Number of votes (shares) and percentage in total number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the Work Report of Board of Directors for 2025	69,197,720 99.9991%	0 0.0000%	600 0.0009%
2.	To consider and approve the Work Report of Board of Supervisors for 2025	69,197,720 99.9991%	0 0.0000%	600 0.0009%
3.	To consider and approve the Audited Consolidated Financial Statements for 2025 and independent auditor’s report for 2025	69,197,720 99.9991%	0 0.0000%	600 0.0009%

Ordinary Resolutions		Number of votes (shares) and percentage in total number of votes (%)		
		For	Against	Abstain
4.	To consider and approve 2025 Annual Report and ESG report	69,197,720 99.9991%	0 0.0000%	600 0.0009%
5.	To consider and approve the final accounts plan for 2025	69,197,720 99.9991%	0 0.0000%	600 0.0009%
6.	To consider and approve profit distribution plan for 2025	69,197,720 99.9991%	0 0.0000%	600 0.0009%
7.	To consider and approve the re-appointment of external auditor for 2026, and to authorize the Board to fix their remuneration	69,197,720 99.9991%	0 0.0000%	600 0.0009%
8.	To consider and approve the Directors' remuneration for 2026	69,197,720 99.9991%	0 0.0000%	600 0.0009%
9.	To consider and approve the application to the banks for the comprehensive credit facilities for 2026 and provision of guarantees	69,197,720 99.9991%	0 0.0000%	600 0.0009%
10.	To consider and approve the abolishment of the Board of Supervisors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
11.	To consider and approve the amendments to Rules of Procedure for Shareholders' Meeting	69,197,720 99.9991%	0 0.0000%	600 0.0009%
12.	To consider and approve the amendments to Rules of Procedure for Meeting of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
13.	The election of Directors of the second session of the Board of Directors	—	—	—
	a. Proposal on the election of Mr. Kang Xinshan as an executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
	b. Proposal on the election of Ms. Feng Yan as an executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
	c. Proposal on the election of Dr. Chen Guangming as an executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
	d. Proposal on the election of Mr. Li Junqing (李俊青先生) as an executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%

Ordinary Resolutions		Number of votes (shares) and percentage in total number of votes (%)		
		For	Against	Abstain
e.	Proposal on the election of Mr. Xu Dong as a non-executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
f.	Proposal on the election of Mr. Wang Xinkun as a non-executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
g.	Proposal on the election of Ms. Wang Shan Shan as an independent non-executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
h.	Proposal on the election of Ms. Pu Meiting as an independent non-executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
i.	Proposal on the election of Mr. Lin Bin (林斌先生) as an independent non-executive Director of the second session of the Board of Directors	69,197,720 99.9991%	0 0.0000%	600 0.0009%
14.	To consider and approve the capital increase in Hong Kong subsidiary	69,197,720 99.9991%	0 0.0000%	600 0.0009%
Special Resolutions		Number of votes (shares) and percentage in total number of votes (%)		
		For	Against	Abstain
15.	To consider and approve the amendments to the Articles of Association	69,197,720 99.9991%	0 0.0000%	600 0.0009%
16.	To consider and approve the formulation of the implementation plan for the share incentive scheme	69,197,720 99.9991%	0 0.0000%	600 0.0009%
17.	To consider and approve the general mandate to issue Shares	69,197,720 99.9991%	0 0.0000%	600 0.0009%
18.	To consider and approve the general mandate to repurchase Shares	69,197,720 99.9991%	0 0.0000%	600 0.0009%

Notes:

- (a) Please refer to the circular of the AGM of the Company dated 30 April 2026 for the full text of the resolutions.
- (b) As more than half of the voting rights held by shareholders (including proxies) present at the AGM were cast in favour of each of the resolutions Nos. 1 to 14, such ordinary resolutions were duly passed.

- (c) As more than two-thirds of the voting rights held by shareholders (including proxies) present at the AGM were cast in favour of each of the resolutions Nos. 15 to 18, such special resolutions were duly passed.
- (d) The total number of issued shares of the Company as at the date of the AGM was 78,707,270. The Company did not hold any treasury shares or repurchased shares pending cancellation as at the date of the AGM.
- (e) The total number of shares of the Company entitling the holders thereof to attend and vote on resolutions at the AGM was 78,707,270. Shareholders or their proxies holding an aggregate of 69,198,320 shares with voting rights (representing approximately 87.92% of the total number of shares of the Company) attended the AGM.
- (f) When voting on the proposals at the AGM, shareholder representative and supervisor representative were jointly responsible for vote taking and vote scrutinizing. Tricor Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for the vote-taking at the AGM.
- (g) There were no Shares entitling the shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules.
- (h) No shareholder was required under the Listing Rules to abstain from voting on any resolution at the AGM.
- (i) No shareholder of the Company has stated their intention in the Company's circular dated 30 April 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (j) All Directors of the Board of the Company attended the AGM either in person or through video or teleconference.

Change of Directors

Dr. Chen Shuyi and Mr. Gong Weimin retired as Directors of the board of directors (the “**Board**”) after the conclusion of the AGM. At the AGM, Mr. Li Junqing was elected as an executive Director, and Mr. Lin Bin was elected as an independent non-executive Director, each for a term of three years, from the conclusion of the AGM until the conclusion of the Company's annual general meeting to be held in 2029.

The Board would like to express its sincere gratitude to Dr. Chen and Mr. Gong for their valuable contributions to the Company during their tenure. Each of Dr. Chen and Mr. Gong has confirmed that he has no disagreement with the Board and is not aware of any matters in relation to his retirement that need to be brought to the attention of the shareholders.

The biographical details of the newly appointed Directors are set out as follows.

Mr. Li Junqing, aged 40, obtained his bachelor's degree in Chinese materia medica from Tianjin University of Traditional Chinese Medicine (天津中醫藥大學) in 2007, his master's degree in pharmacology of Chinese materia medica from the same university in 2010, and his doctoral degree in pharmacology from Beijing University of Traditional Chinese Medicine (北京中醫藥大學) in 2013. He joined the Company in July 2013, currently serves as head of the preclinical research center and concurrently as head of the medical center. Dr. Li Junqing is the clinical technical lead of the Company's innovative drug projects, responsible for the pharmacological and clinical research of innovative drugs. He has extensive experience in preclinical and clinical studies of new drugs. He has participated in multiple national major new drug innovation program and national "973" program projects. He has published six papers as the first author in core journals, along with 14 other papers and conference articles. He has filed three domestic invention patents and six international patents.

Mr. Lin Bin, aged 44, graduated from The Open University of Fujian (福建廣播電視大學) in July 2003, majoring in computer application. He obtained his bachelor's degree in Management, majoring in Accounting, from Putian University (莆田學院) in January 2014. From August 2006 to July 2021, Mr. Lin served as Manager of the Innovation Office, Putian Business Department, Fujian Branch of China UnionPay Merchant Services Company Limited. Since August 2021, Mr. Lin has served as Manager of the Marketing Department of Putian Meiou Medical Beauty Co., Ltd.* (莆田美歐醫學美容有限公司).

Mr. Lin has confirmed (i) his independence with respect to each of the factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Group, or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, each of Mr. Li and Mr. Lin has also confirmed that he (i) has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions with the Company or its subsidiaries; (iii) does not have other major appointments and professional qualifications; and (iv) does not have any relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company.

As at the date of this announcement, Mr. Lin does not have any interest in any shares, underlying shares or debentures of the Company and/or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Mr. Lin has taken legal advice as required under Rule

3.09D of the Listing Rules and has confirmed that he understands his duties as a director. Mr. Lin has also confirmed that he meets the independence guidelines set out in Rule 3.13 of the Listing Rules. As at the date of this announcement, Mr. Li has contributed RMB229,590 to Xiamen Tairuihe Investment Partnership (Limited Partnership), representing 2.2959% of the total capital contribution of that enterprise; and RMB50,000 to Xiamen Tairuihong Investment Partnership (Limited Partnership), representing 0.7657% of the total capital contribution of that enterprise. Mr. Li has taken legal advice as required under Rule 3.09D of the Listing Rules and has confirmed that he understands his duties as a director.

Following the approval by the shareholders of resolution No. 8 at the AGM, the Directors' remuneration is set out as follows:

- (1) Executive Directors and non-executive Directors will not receive any Director's fee. A director serving the Company shall receive remuneration for his/her substantive position(s) held in the Company;
- (2) Independent non-executive Directors shall be entitled to an annual allowance of RMB120,000 (before tax) per person per annum.

Save for the information disclosed above, each of Mr. Li and Mr. Lin has confirmed that there is no other information required to be disclosed under Rule 13.51(2) of the Listing Rules, nor is the Company aware of any matters in relation to the appointment of Mr. Li and Mr. Lin that need to be brought to the attention of the shareholders.

The Board would like to take this opportunity to welcome Mr. Li and Mr. Lin for joining the Board.

Election of Chairman and Appointment of Senior Management

After the conclusion of the AGM, the second session of the Board convened its first meeting (the "**Board Meeting**").

At the Board Meeting, the Board elected Kang Xinshan as the Chairman of the second session of the Board, for a term of three years commencing from the date of the Board Meeting.

At the Board Meeting, the Board also appointed (i) Kang Xinshan as the General Manager of the Company; (ii) Ms. Feng Yan as a Deputy General Manager of the Company; (iii) Dr. Chen Guangming as a Deputy General Manager of the Company; (iv) Dr. Zhang Mingqiang as a Deputy General Manager of the Company; and (v) Ms. Zhang Junhuan as the Board Secretary and Chief Financial Officer of the Company.

Change in Composition of Board Committee

Following the election and approval by the Directors at the Board Meeting, the composition of each Board committee under the second session of the Board is as follows:

Audit Committee

Ms. Pu Meiting (Chairperson), Mr. Lin Bin, Ms. Wang Shanshan

Strategy Committee

Dr. Kang Xinshan (Chairperson), Ms. Feng Yan, Mr. Lin Bin

Nomination Committee

Ms. Wang Shanshan (Chairperson), Ms. Pu Meiting, Dr. Kang Xinshan

Remuneration and Appraisal Committee

Ms. Wang Shanshan (Chairperson), Dr. Kang Xinshan, Ms. Pu Meiting

Abolishment of the Board of Supervisors

Reference is also made to the circular of the Company dated 30 April 2026 regarding the proposed amendments to the Articles of Association of the Company, which included, among other things, the abolishment of the Board of Supervisors and the exercise of its functions and powers by the Audit Committee of the Board.

Accordingly, the Board announces that, following the approval by the shareholders of the proposed amendments to the Articles of Association and abolishment of the Board of Supervisors at the AGM, with effect from the date of the AGM, the Company will no longer establish the Board of Supervisors, and the Rules of Procedure of the Board of Supervisors will be abolished simultaneously. Each supervisor of the Company (the “**Supervisor(s)**”) retired from office following the conclusion of the AGM, and each of them has confirmed that they have no disagreement with the Board, nor are there any other matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders.

The Board would like to express its sincere gratitude to each Supervisor for their valuable contributions and services rendered to the Company during their tenure as Supervisors.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 27 May 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Mr. Li Junqing as executive Directors; (ii) Mr. Wang Xinkun and Mr. Xu Dong as non-executive Directors; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.

* *For identification purposes only*